Profound Medical Corp. (PROF) Fair Value 2026

PROF · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.8 /10

32 fundamental signals · 2 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-28, Profound Medical Corp. (PROF) trades at $6.85, versus a $3.34 median fair value across its 2 active models — 51.3% below the current price. QOC: 6.8/10. Value Trap Risk: 26/100 (LOW). 2/13 models active.

Key Facts

Ticker
PROF
Price
$6.85
Quality Score
6.8/10
Value Trap Risk
26/100
Models Active
2/13
Last Updated
Strength: 2 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Profound Medical Corp. (PROF) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Profound Medical Corp. (PROF) appears overvalued as of : the median of 2 independent fair value estimates is $3.34, 51.3% below the current price of $6.85. Estimates range from $0.36 to $6.32. PROF scores 6.8/10 on fundamental quality and 26/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. PROF’s -51.3% gap is wider than that market norm, and the Medical Devices sector median is -43.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Profound Medical Corp. Stock in 2026? →

What Fair Value Does Each Model Give PROF?

2 Intrinsic Value Models vs. Current Price ($6.85)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.36 -94.8%
Relative · Low Conviction
 $6.32 -7.7%

All Models Active

All 2 models are displayed above.

What Is Profound Medical Corp. (PROF) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Profound Medical Corp.'s intrinsic value is estimated at $3.34, suggesting the stock is overvalued at its current price of $6.85. With 2 out of 2 models flagging downside (-51.3% vs price), the market may be pricing in unsustainable growth. Model dispersion is worth noting: FTNN targets $6.32 (-7.7%), versus ML-RIV at $0.36 (-94.8%). This +87.0% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About PROF?

2 of 13 models are currently active for PROF. All 2 active models suggest the stock trades above fair value. Taken together, their median fair value for PROF is $3.34 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does PROF Rank in Medical Devices?

Among 159 Medical Devices stocks, PROF ranks #59 by Quality of Company score. CirclFi's QOC score of 6.8/10 evaluates 32 fundamental signals. A score of 6.8 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

Within the Medical Devices space, Profound Medical Corp. competes in an environment where revenue per drug often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is PROF a Value Trap?

CirclFi's Value Trap algorithm assigns PROF a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Profound Medical Corp.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Profound Medical Corp. is rated at 6.8/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

The gap between the most bullish and bearish model spans +87.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PROF valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PROF's 2 active models, average confidence is 31%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Profound Medical Corp. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

HYPRHyperfine, Inc.QOC 6.8GKOSGlaukos CorporationQOC 6.7SENSSenseonics Holdings, Inc.QOC 6.8RCELAVITA Medical, Inc.QOC 6.7NEOGNeogen CorporationQOC 6.9INGNInogen, Inc.QOC 6.7QDELQuidelOrtho CorporationQOC 5.8MODDModular Medical, Inc.QOC 4.4CNMDCONMED CorporationQOC 8.5IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: HYPR · GKOS · SENS · RCEL · NEOG · INGN · QDEL · MODD · CNMD · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to PROF?

7 companies across all industries closest to PROF’s Quality of Company score of 6.8/10.

GOAIEva Live, Inc.QOC 6.8BAFNBayFirst Financial Corp.QOC 6.8RXORXO, Inc.QOC 6.8GRABGrab Holdings LimitedQOC 6.8HZOMarineMax, Inc.QOC 6.8CSBRChampions Oncology, Inc.QOC 6.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GOAI · BAFN · RXO · GRAB · HZO · CSBR · NVDA

Where Does PROF Sit in CirclFi's Medical Devices Rankings?

PROF is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Profound Medical Corp.’s Valuation?

What is Profound Medical Corp.'s intrinsic value in 2026?

CirclFi puts Profound Medical Corp. (PROF)'s intrinsic value at $3.34 — the median of 2 independent model estimates as of 2026-08-28, ranging from $0.36 to $6.32. The Quality of Company score is 6.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PROF overvalued or undervalued right now?

At $6.85, 0 of 2 active models suggest PROF may be undervalued, while 2 indicate potential overvaluation. The median of all 2 fair value estimates is $3.34, 51.3% below the current price of $6.85 — a consensus view that PROF is overvalued. The assessment depends on which methodology best fits Profound Medical Corp.'s business model in Medical Devices.

What does a Quality of Company score of 6.8 mean for PROF?

Profound Medical Corp.'s QOC of 6.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on PROF?

CirclFi analyzes PROF with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is PROF a value trap in 2026?

Profound Medical Corp.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Profound Medical Corp. (PROF) has a median fair value of $3.34 — 51.3% below the current price of $6.85 — as of 2026-08-28.” Source: circlfi.com/stock/PROF/ · Methodology
Primary sources for this PROF valuation
  • Financial statements: Profound Medical Corp. 10-K and 10-Q filings on SEC EDGAR (CIK 0001628808) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PROF as of ; valuations recomputed .